Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy shot could replace monthly eye injections for wet AMD

NCT ID NCT04514653

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Nov 16, 2025 · Last updated Apr 24, 2026 · Updated 15 times

Summary

This study tests a gene therapy called RGX-314 as a potential one-time treatment for wet age-related macular degeneration (nAMD), a leading cause of vision loss. Currently, patients need frequent eye injections to control the disease. The trial involves about 146 participants and compares the gene therapy to standard ranibizumab injections. The goal is to see if RGX-314 can maintain vision with fewer treatments, though ongoing monitoring is still needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • California Retina Consultants - Bakersfield /ID# 255910

    Bakersfield, California, 93309-1677, United States

  • California Retina Consultants - Santa Barbara /ID# 255923

    Santa Barbara, California, 93103, United States

  • Charles Retina Institute /ID# 255922

    Germantown, Tennessee, 38138, United States

  • Duke University Medical Center /ID# 267646

    Durham, North Carolina, 27710, United States

  • Eye Associates of New Mexico /ID# 255915

    Albuquerque, New Mexico, 87109, United States

  • Johns Hopkins Hospital /ID# 255919

    Baltimore, Maryland, 21287, United States

  • Mid Atlantic Retina /ID# 255906

    Philadelphia, Pennsylvania, 19107, United States

  • Northern California Retina Vitreous Associates Medical Group, Inc /ID# 255920

    Mountain View, California, 94040-4101, United States

  • Ophthalmic Consultants of Boston /ID# 255917

    Boston, Massachusetts, 02114, United States

  • Retina Consultants - The Woodlands /ID# 255924

    The Woodlands, Texas, 77384, United States

  • Retina Consultants of San Diego /ID# 255911

    Poway, California, 92064-2530, United States

  • Retina Vitreous Assoc Med Grp /ID# 255921

    Beverly Hills, California, 90211, United States

  • Retinal Diagnostic Center /ID# 272275

    Campbell, California, 95008, United States

  • Retinal Research Institute /ID# 255925

    Phoenix, Arizona, 85053, United States

  • Sierra Eye Associates /ID# 255908

    Reno, Nevada, 89502, United States

  • Southeast Retina Center /ID# 255912

    Augusta, Georgia, 30909, United States

  • Springfield Clinic - First /ID# 272274

    Springfield, Illinois, 62702, United States

  • Tennessee Retina - Nashville /ID# 255918

    Nashville, Tennessee, 37203-1513, United States

Conditions

Explore the condition pages connected to this study.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)